← Back to GLP-1 DatabaseActive Ingredient tirzepatide Drug Class Dual GIP/GLP-1 Receptor Agonist Dosage & Administration Injectable Approved Indications Weight Loss & Type 2 Diabetes FDA Approved May 13, 2022
Mounjaro
tirzepatide
Dual GIP/GLP-1 Receptor AgonistInjectableWeight Loss & Type 2 Diabetes
Manufacturer: Eli LillyFDA Approved: May 13, 2022Starting from $1250.00/mo
Overview
Mounjaro is a once-weekly dual GIP/GLP-1 receptor agonist approved for type 2 diabetes, with significant weight loss effects.
Clinical Data
Weight Loss Efficacy
~21% body weight loss in SURMOUNT trials
Common Side Effects
nauseadiarrheadecreased appetitevomitingconstipation
Community Side-Effect Reports
User-reported data — not medical advice. Consult your healthcare provider.
Provider Pricing
Hims & Hers
$1499.00/mo
✓Consultation included
Mochi Health
$1250.00/mo
+ consultation fee: $50.00
PlushCare
$1500.00/mo
+ consultation fee: $129.00
Calibrate
$1400.00/mo
✓Consultation included